Companies › CytomX Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CX-2051 Probody therapeutic | – | Phase 1 | Solid Tumor, Adult | Nov 2027 |
| CX-801 Probody therapeutic (engineered antibody) | – | Phase 1 | Solid Tumor, Adult | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06265688 | CX-2051 | Phase 1 | Solid Tumor, Adult | Oncology | Nov 2027 |
| NCT06462794 | CX-801 | Phase 1 | Solid Tumor, Adult | Oncology | Feb 2028 |
Cash and short-term investments of $348m on 2026-09-30; operating cash outflow about $36m a year; runway about 115 months at that burn, to May 2036
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.